Journal article
Going to extremes: determinants of extraordinary response and survival in patients with cancer
FAM Saner, A Herschtal, BH Nelson, A deFazio, EL Goode, SJ Ramus, A Pandey, JA Beach, S Fereday, A Berchuck, S Lheureux, CL Pearce, PD Pharoah, MC Pike, DW Garsed, DDL Bowtell
Nature Reviews Cancer | NATURE PUBLISHING GROUP | Published : 2019
Abstract
Research into factors affecting treatment response or survival in patients with cancer frequently involves cohorts that span the most common range of clinical outcomes, as such patients are most readily available for study. However, attention has turned to highly unusual patients who have exceptionally favourable or atypically poor responses to treatment and/or overall survival, with the expectation that patients at the extremes may provide insights that could ultimately improve the outcome of individuals with more typical disease trajectories. While clinicians can often recount surprising patients whose clinical journey was very unusual, given known clinical characteristics and prognostic i..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
F.A.M.S. is supported by a Swiss National Foundation Early Postdoc Mobility Fellowship (P2BEP3-172246), Swiss Cancer Research Foundation grant BIL KFS-3942-08-2016 and a Professor Dr Max Cloetta and Uniscientia Foundation grant. B.H.N., A.dF., C.L.P., M.C.P., D.W.G. and D.D.L.B. are supported by US Army Medical Research and Materiel Command grant W81XWH-16-2-0010. D.D.L.B. is supported by National Health and Medical Research Council of Australia (NHMRC) grants APP1092856 and APP1117044 and by the US National Cancer Institute U54 programme (U54CA209978). The authors acknowledge additional support from Margaret Rose AM and the Rose family, The WeirAnderson Foundation, Border Ovarian Cancer Awareness Group, donors to the Garvan Institute of Medical Research Ovarian Cancer Research Program, the Peter MacCallum Cancer Foundation, Wendy Taylor and Arthur Coombs and family. The Australian Ovarian Cancer Study (AOCS) was supported by the US Army Medical Research and Materiel Command under DAMD17-01-1-0729.